Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas

医学 耐火材料(行星科学) 淋巴瘤 癌症研究 机制(生物学) 免疫学 生物 物理 量子力学 天体生物学
作者
Stephen J. Schuster,Ling‐Yuh Huw,Christopher R. Bolen,Victor D Maximov,Andrew G. Polson,Katerina Hatzi,Elisabeth A. Lasater,Sarit E. Assouline,Nancy L. Bartlett,Lihua Elizabeth Budde,Matthew J. Matasar,Hartmut Koeppen,Emily C. Piccione,Deanna Wilson,Michael C. Wei,Shen Yin,Elicia M. Penuel
出处
期刊:Blood [Elsevier BV]
卷期号:143 (9): 822-832 被引量:96
标识
DOI:10.1182/blood.2023022348
摘要

ABSTRACT: CD20 is an established therapeutic target in B-cell malignancies. The CD20 × CD3 bispecific antibody mosunetuzumab has significant efficacy in B-cell non-Hodgkin lymphomas (NHLs). Because target antigen loss is a recognized mechanism of resistance, we evaluated CD20 expression relative to clinical response in patients with relapsed and/or refractory NHL in the phase 1/2 GO29781 trial investigating mosunetuzumab monotherapy. CD20 was studied using immunohistochemistry (IHC), RNA sequencing, and whole-exome sequencing performed centrally in biopsy specimens collected before treatment at predose, during treatment, or upon progression. Before treatment, most patients exhibited a high proportion of tumor cells expressing CD20; however, in 16 of 293 patients (5.5%) the proportion was <10%. Analyses of paired biopsy specimens from patients on treatment revealed that CD20 levels were maintained in 29 of 30 patients (97%) vs at progression, where CD20 loss was observed in 11 of 32 patients (34%). Reduced transcription or acquisition of truncating mutations explained most but not all cases of CD20 loss. In vitro modeling confirmed the effects of CD20 variants identified in clinical samples on reduction of CD20 expression and missense mutations in the extracellular domain that could block mosunetuzumab binding. This study expands the knowledge about the occurrence of target antigen loss after anti-CD20 therapeutics to include CD20-targeting bispecific antibodies and elucidates mechanisms of reduced CD20 expression at disease progression that may be generalizable to other anti-CD20 targeting agents. These results also confirm the utility of readily available IHC staining for CD20 as a tool to inform clinical decisions. This trial was registered at www.ClinicalTrials.gov as #NCT02500407.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
kiluto发布了新的文献求助10
1秒前
搞怪达完成签到,获得积分10
1秒前
包包完成签到,获得积分10
1秒前
大模型的应助被cc2004bj采纳,获得10
2秒前
毕不了业要赔钱完成签到,获得积分10
3秒前
小y完成签到,获得积分10
3秒前
lisastream完成签到,获得积分10
3秒前
dian完成签到,获得积分10
4秒前
无花果的应助被XPR采纳,获得10
4秒前
4秒前
虫子完成签到,获得积分10
7秒前
7秒前
hkh完成签到,获得积分10
8秒前
科研通AI65的应助被迷路的夏之采纳,获得10
9秒前
Lucas的应助被原点采纳,获得10
9秒前
9秒前
淡然紫菜完成签到,获得积分10
10秒前
10秒前
deardorff完成签到,获得积分10
11秒前
冷静勒完成签到,获得积分10
11秒前
哈基米完成签到,获得积分0
12秒前
荣荣发布了新的文献求助10
13秒前
13秒前
田様的应助被huwenbin采纳,获得10
13秒前
111完成签到,获得积分10
14秒前
14秒前
14秒前
14秒前
fantasy的应助被王大橙子采纳,获得10
15秒前
15秒前
znznznzn1234发布了新的文献求助10
16秒前
迷路的夏之完成签到,获得积分10
17秒前
Steven完成签到 ,获得积分10
18秒前
XPR发布了新的文献求助10
19秒前
fantasy的应助被科研小虫采纳,获得10
19秒前
20秒前
20秒前
194完成签到,获得积分10
21秒前
cscgood完成签到,获得积分10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181823
求助须知:如何正确求助?哪些是违规求助? 9571511
关于积分的说明 21818391
捐赠科研通 7778076
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479614